Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | HSPB1 | P04792 | 3/20 | 0.39 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | AGXT | P21549 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30523912 | 1.00 | CES2 (0.39) | CES2CES1HSPB1CA3CA6 | |
| SCHEMBL1484426 | 0.84 | IDO1 (0.43) | CES2CES1HSPB1CA3CA6 | |
| SCHEMBL28541327 | 0.83 | HSPB1 (0.37) | CES2CES1HSPB1CA3CA6 | |
| SCHEMBL3269792 | 0.83 | HSPB1 (0.37) | CES2CES1HSPB1CA3CA6 | |
| SCHEMBL4087411 | 0.83 | CA3 (0.43) | CES2CES1CA3CA6CA5A | |
| SCHEMBL30300590 | 0.83 | CA3 (0.43) | CES2CES1CA3CA6CA5A | |
| SCHEMBL31030938 | 0.81 | ESR1 (0.38) | — | |
| SCHEMBL31114606 | 0.81 | CA3 (0.46) | CA3CA6CA5ACA9CA14 | |
| SCHEMBL31055822 | 0.80 | ESR2 (0.49) | — | |
| SCHEMBL2414121 | 0.79 | PPARG (0.45) | MAPTHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118336009-A | Phenylboronic acid-based additive and electrolyte for lithium/carbon fluoride primary battery | 上海大学 | 2024-07-12 | — | — | CN | claimed |
| CN-114262330-B | Fascaplysin derivative, preparation method and application thereof in resisting MRSA | 宁波大学 | 2023-12-12 | — | — | CN | claimed |
| EP-1506176-B1 | AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM | PFIZER ITALIA SRL (IT) | 2013-04-24 | — | — | EP | claimed |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | HINOVA PHARMACEUTICALS INC (CN) | 2026-01-15 | — | — | US | disclosed |
| EP-4553075-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | Hinova Pharmaceuticals Inc. (CN) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024199444-A1 | HETEROAROMATIC RING COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海翊维康医药有限责任公司 | 2024-10-03 | — | — | WO | disclosed |
| CN-118336009-A | Phenylboronic acid-based additive and electrolyte for lithium/carbon fluoride primary battery | 上海大学 | 2024-07-12 | — | — | CN | disclosed |
| CN-118271331-A | Gelsemin derivatives, synthesis method and application thereof in inhibiting tumor cell proliferation | 赣江中药创新中心 | 2024-07-02 | — | — | CN | disclosed |
| CN-114262330-B | Fascaplysin derivative, preparation method and application thereof in resisting MRSA | 宁波大学 | 2023-12-12 | — | — | CN | disclosed |
| CN-116761834-A | Storage stable epoxy resin composition | 澳泽化学特罗斯特贝格有限公司 | 2023-09-15 | — | — | CN | disclosed |
| CN-114207024-B | Storage stable epoxy resin composition | 澳泽化学特罗斯特贝格有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20030080342-A1 | Light-emitting element and novel iridium complexes | FUJI PHOTO FILM CO., LTD. | 2003-05-01 | — | — | US | disclosed |
| EP-0675118-B1 | Biphenylderivatives, process for their preparation and their use as medicaments | EISAI CO LTD (JP) | 2002-10-09 | — | — | EP | disclosed |
| US-6455720-B1 | AS CATALYSTS | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-05-16 | — | — | US | disclosed |
| WO-2002036639-A2 | FLUORINATED ZWITTERIONIC COCATALYST ACTIVATORS FOR OLEFIN POLYMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-1167372-A1 | 2,2-(Diaryl)vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | Takasago International Corporation (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6281214-B1 | USEFUL FOR TREATING AND AMELIORATING MENTAL DISORDERS | EISAI CO., LTD (JP) | 2001-08-28 | — | — | US | disclosed |
| EP-0675118-A2 | Biphenylderivatives, process for their preparation and their use as medicaments | Eisai Co., Ltd. (JP) | 1995-10-04 | — | — | EP | disclosed |
| EP-0189799-A1 | Process for separating cesium ions from aqueous solutions | KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH (DE) | 1986-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058837-A1 | 2,2 (Diarlyl) Vinylphosphine compound, palladium catalyst thereof, and process for producing arylamine, diaryl, or arylalkyne with the catalyst | DDT, PDCD11, PLD2 | CES2 3946/4885CES1 3736/4885HSPB1 4793/4885 |
| US-20260015341-A1 | PI3K INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF | PIK3CA, PIK3R4, PIK3R1 | CES2 1448/4885CES1 97/4885HSPB1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.